


Cite this: *Analyst*, 2024, **149**, 4179

# Forced intercalation-induced light-up peptides as fluorogenic indicators for the HIV-1 TAR RNA-ligand assay†

En Ting Tabitha Lee, Yusuke Sato, \* Akunna F. Ujuagu and Seiichi Nishizawa \*

Fluorescence indicators capable of binding to human immunodeficiency virus-1 (HIV-1) *trans*-activation responsive (TAR) RNA are powerful tools for the exploratory studies of the identification of anti-HIV drug candidates. This work presents a new design strategy for fluorogenic indicators with a transactivator of transcription (Tat)-derived peptide based on the forced intercalation of thiazole orange (TO) dyes (FIT). The developed 9-mer FIT peptide (RKKRR-TO-RRR; named FiLuP) features the TO unit integrated onto a Dap (2,3-diaminopropionic acid) residue in the middle of the Tat peptide sequence; the Q (glutamic acid) residue in the Tat peptide (RKKRR-Q-RRR) is replaced with TO as if it were an amino acid surrogate. This facilitates a significant light-up response (450-fold at  $\lambda_{em} = 541$  nm,  $\Phi_{free} = 0.0057$ , and  $\Phi_{bound} = 0.61$ ) upon binding to TAR RNA. The response of FiLuP is highly selective to TAR RNA over other non-cognate RNAs, and FiLuP maintains strong binding affinity ( $K_d = 1.0 \pm 0.6$  nM). Significantly, in contrast to previously developed Tat peptide-based FRET probes, FiLuP is able to discriminate between "competitive" and "noncompetitive" inhibitors when used in the fluorescence indicator displacement (FID) assay. The FID assay under stringent screening conditions is also possible, enabling super-strong competitive binders toward TAR RNA to be sieved out.

Received 8th April 2024,  
Accepted 28th May 2024

DOI: 10.1039/d4an00530a

rsc.li/analyst

## Introduction

With increasing knowledge about the diverse roles of RNAs within the cells, RNA-binding ligands have received considerable attention in drug discovery.<sup>1,2</sup> Human immunodeficiency virus-1 (HIV-1) *trans*-activation responsive (TAR) RNA plays a pivotal role in the replication of HIV-1 through binding to the transactivator of transcription (Tat) protein, making it an important therapeutic target for anti-HIV strategies.<sup>3</sup> TAR RNA consists of 59 nucleotides located at the 5' end of viral mRNAs, forming a stem-loop structure with a three-nucleotide (UCU) bulge (*cf.* Fig. 2A). It has been well known that Tat protein binds specifically to the three-nucleotide bulge region in TAR RNA, and the binding is mediated by a single arginine (R) within a nine residue stretch of basic amino acids (residues 49 to 57: R<sub>49</sub>KKRRQRRR<sub>57</sub>).<sup>4</sup> The identification of TAR RNA-binding ligands capable of interfering with the formation of a

Tat protein complex represents a promising avenue for potential anti-HIV drugs.<sup>5</sup>


In this context, fluorescence methods are commonly employed for the exploratory studies of RNA-targeted ligands as they have several advantages such as sensitivity, speed and the convenient availability of equipment. In particular, the fluorescence indicator displacement (FID) assay is a simple and high-throughput method without fluorophore labeling of both target RNAs and test compounds used in screening experiments.<sup>6</sup> While several fluorescent small molecules have been proposed for the FID assay,<sup>7</sup> the most widely employed indicator for TAR RNA is based on Förster resonance energy transfer (FRET) with a truncated peptide comprising the basic domain of Tat protein (Tat<sub>49–57</sub>: R<sub>49</sub>K<sub>50</sub>K<sub>51</sub>R<sub>52</sub>R<sub>53</sub>Q<sub>54</sub>R<sub>55</sub>R<sub>56</sub>R<sub>57</sub>).<sup>8</sup> A Tat<sub>49–57</sub>-containing 16-mer peptide (AAA-R<sub>49</sub>KKRRQRRR<sub>57</sub>-AAAC) labelled with 5-carboxy-fluorescein and tetramethylrhodamine at the N-terminus and C-terminus, respectively, showed an increase in the FRET efficiency upon binding to TAR RNA, whereas the binding of the test compounds decreased the FRET efficiency (Fig. 1). To date, this FRET peptide probe has been widely used for functional evaluation of TAR RNA-binding ligands (Tat antagonists) discovered by *in silico* screening or structure-based design,<sup>9</sup> and it has also been used for high-throughput screening (HTS) with ~100 000 compounds.<sup>10</sup>

Department of Chemistry, Graduate School of Science, Tohoku University, Sendai 980-8578, Japan. E-mail: yusuke.sato.a7@tohoku.ac.jp, seiichi.nishizawa.c8@tohoku.ac.jp

†Electronic supplementary information (ESI) available: Experimental details, probe synthesis, fluorescence response, salt dependence of the binding affinity, and FID results. See DOI: <https://doi.org/10.1039/d4an00530a>



## Forced intercalation-induced light-up peptide (FiLuP) probe



**Fig. 1** Schematic illustration of the Tat peptide-based fluorogenic probe based on forced intercalation of the TO unit integrated into the middle of the peptide sequence as if it were a substitute for the amino acids that make up the Tat peptide. A traditional FRET-based probe was also shown as a comparison.

Nevertheless, its fluorescence response for TAR RNA was quite modest, typically less than 3-fold,<sup>8,11</sup> which poses a disadvantage in terms of the detection sensitivity of the displacement events. Recently, an aggregation induced emission (AIE) fluorogen (tetraphenylethylene: TPE) was newly used for the Tat peptide-based indicator design (TPE-G-R<sub>49</sub>KKRRQRRR<sub>57</sub>-PPQG);<sup>12</sup> however, it did not result in an improvement in the fluorescence response (3-fold). Considering how the low fluorescence response of the indicator hampers the performance of the FID assay, including its reproducibility, robustness and reliability,<sup>6</sup> there is a significant need to design Tat peptide-based indicators with large fluorescence signaling properties.

This paper presents a new design strategy for Tat peptide probes based on the forced intercalation of thiazole orange (TO) dyes (FIT).<sup>13</sup> The Seitz group showed that a TO unit connected to a DNA backbone as a base surrogate by a short spacer could forcibly intercalate into predetermined base pairs of the duplex structure formed through hybridization with a complementary sequence.<sup>14</sup>

These FIT oligonucleotide probes (named FIT probes) display significant light-up properties, enabling the sensitive detection of target DNAs/RNAs. FIT was recently used for the design of DNA aptamers for the sensing of metal ions and proteins.<sup>15</sup> FIT sensing was also achieved in peptide nucleic acid (PNA) probes for single-stranded RNAs,<sup>16</sup> followed by in triplex-forming PNA probes<sup>17,18</sup> for double-stranded RNAs by our group.<sup>19</sup>

Taking inspiration from these successes in oligonucleotide probes, we integrated FIT-sensing into the design of Tat peptide probes as novel fluorescence indicators for TAR RNA, where one amino acid in the Tat peptide (the basic domain of

Tat protein: R<sub>49</sub>K<sub>50</sub>K<sub>51</sub>R<sub>52</sub>R<sub>53</sub>Q<sub>54</sub>R<sub>55</sub>R<sub>56</sub>R<sub>57</sub>) was replaced with TO as if it were an amino acid surrogate (Fig. 1 and 2A). Designing FIT peptides named FIT light-up peptide (FiLuP) probes, however, presents a challenge because of the inherent complexity of RNA-protein complexes compared to previous oligonucleotide scaffolds. We hypothesized that it could be achieved by strategically positioning the TO unit within the peptide sequence of the basic domain. Specifically, we aimed to place the TO unit in close proximity to the double-stranded RNA region for complex formation with TAR RNA while preserving the amino acid residues crucial for the binding of the Tat peptide. The designed 9-mer FiLuP probe (Fig. 2A, R<sub>49</sub>KKRR-TO-RRR<sub>57</sub>) exhibited a significant light-up response (450-fold) upon strong and selective binding to TAR RNA ( $K_d$  = 1.0 nM), which is clearly superior to the previously-developed 16-mer Tat peptide-based FRET probes ( $K_d$  = 23.6 to 286 nM).<sup>8,11</sup> In comparison with a conventional peptide probe appended with the TO unit through a flexible spacer at the N-terminal (TO-R<sub>49</sub>KKRRQRRR<sub>57</sub>), we found that FiLuP had not only a larger response but also higher selectivity, showing the usefulness of FIT sensing for the fluorogenic probe design toward TAR RNA. Significantly, when used in the FID assay, FiLuP is able to discriminate between “competitive” and “non-competitive” inhibitors, which has never been demonstrated with all previous indicators for TAR RNA.<sup>7,8,11,12</sup> In addition, thanks to its strong binding affinity and significant light-up properties, the FID assay under stringent screening conditions can be performed, which sieves out the super-strong competitive inhibitor whose binding affinity is comparable to that of the wild Tat protein. These features of FiLuP are discussed as a basis for the advanced design of peptide-based fluorogenic probes for RNA sensing.


## Experimental

The FRET probe (5-FAM-AAA-R<sub>49</sub>KKRRQRRR<sub>57</sub>-AAK-TAMRA)<sup>11</sup> was purchased from Hipec Laboratories (Kyoto, Japan). FiLuP (R<sub>49</sub>KKRR-TO-RRR<sub>57</sub>) and its variant probes were synthesized by Fmoc solid phase synthesis using a microwave-assisted peptide synthesizer. The crude probes were purified by reverse-phase HPLC (Fig. S1†), followed by verification by MALDI-TOF-MS (Table S1†). A conventional peptide probe appended with the TO unit through a lysine spacer at the N-terminal (TO-R<sub>49</sub>KKRRQRRR<sub>57</sub>) was also prepared (Table S1†). For experimental details and characterization, see the ESI.†

Unless otherwise mentioned, all measurements were performed at 25 °C in 1 × PBS buffer (pH 7.4). Before measurements, annealing of RNA-containing samples was conducted as follows: heated at 95 °C for 10 min and gradually cooled to 25 °C (1 °C min<sup>-1</sup>). Errors denote the standard deviations obtained from at least three independent experiments.

The dissociation constant ( $K_d$ ) for the binding of the probes to target RNA was determined by fluorescence titration experiments. The resulting titration curve was analysed based on a





**Fig. 2** (A) Chemical structure of the FiLuP probe ( $R_{49}KKRR$ -TO- $RRR_{57}$ ) for TAR RNA. The sequence and secondary structure of HIV-1 TAR RNA (31-mer: G16 to C46) used in this study is also shown. (B) Fluorescence spectra of FiLuP (50 nM) in the (a) absence and presence of 50 nM target RNA; (b) TAR RNA, (c) A-site RNA, and (d) influenza A virus promoter RNA. Inset: Fluorescence titration curve for the binding of FiLuP (25 nM) to TAR RNA (0–125 nM). (C) Comparison of the fluorescence intensity of the probes (50 nM) in the absence and presence of various RNAs (50 nM). Excitation: 524 nm (FiLuP), 497 nm (FRET probe), and 521 nm (conventional probe). Analysis: 541 nm (FiLuP), 585 nm (FRET probe), and 534 nm (conventional probe). FRET probe: 5-FAM-AAA- $R_{49}KKRRQRRR_{57}$ -AAAK-TAMRA. Conventional probe: TO- $R_{49}KKRRQRRR_{57}$ .

1 : 1 binding fitting model. Further details are provided in the ESI.†

The FID assay was carried out with FiLuP as a fluorescence indicator. After the FiLuP/TAR RNA complex was formed by the annealing procedure as shown above, the test compounds were added and incubated for 10 min. The fluorescence response of the FiLuP/TAR RNA complex to the test compounds was then measured. The details are also shown in the ESI.†

## Results and discussion

The FiLuP probe for TAR RNA was designed by integrating the TO unit into the Tat<sub>49–57</sub> sequence (Fig. 2A). We decided to strategically replace the Q<sub>54</sub> (glutamic acid) residue with a Dap (2,3-diaminopropionic acid) residue to which the TO unit was connected, based on the reports that the mutation of this residue minimally affects the RNA binding of the Tat peptide.<sup>20</sup> Furthermore, the Q<sub>54</sub> residue was shown to be located close to the double-stranded region of TAR RNA in the relevant Tat/TAR RNA complex structure.<sup>21</sup> This observation suggests that the incorporation of the TO unit at this position would facilitate efficient FIT upon probe binding. The FiLuP probe ( $R_{49}KKRR$ -TO- $RRR_{57}$ ) was synthesized by Fmoc solid phase synthesis, where a TO derivative with a methylcarboxyl group on its quinoline ring was coupled with a Dap residue after the peptide assembly (see the ESI†). Fig. 2B shows the fluorescence response of the probe (50 nM) to 31-mer model TAR RNA at 25 °C in PBS buffer. The probe shows negligible emission of the TO unit ( $\Phi_{\text{free}} = 0.0057$ ) in the absence of RNAs due to the free rotation between two heterorings.<sup>13</sup> The addition of equimolar target RNA (50 nM) caused a significant light-up response (450-fold increase) of the TO unit ( $\lambda_{\text{em}} = 541$  nm). This indicates that the TO unit is forced to intercalate

into the base pairs of the double-stranded region of RNA upon probe binding.<sup>19</sup>


The fluorescence quantum yield of the probe in the bound state with target RNA ( $\Phi_{\text{bound}}$ ) reaches as much as 0.61. Actually, the observed light-up response of FiLuP is superior to those of FIT oligonucleotide probes with the TO base surrogate,<sup>14,15,19</sup> showing the usefulness of RNA-binding peptides as molecular scaffolds for FIT sensing. It is noteworthy that the light-up response of FiLuP is highly superior to that of the previously-developed Tat peptide-based FRET probe<sup>11</sup> that shows a fluorescence increase of only 1.2-fold under identical conditions (Fig. 2C and S2A†). Also, the light-up response of FiLuP is highly superior to that of the Tat peptide-based probe with AIE fluorogens, where the fluorescence intensity was reported to increase by 3-fold in the presence of 600 nM TAR RNA.<sup>12</sup> Moreover, our probe has excellent binding properties toward TAR RNA. The dissociation constant ( $K_d$ ) of FiLuP based on a 1 : 1 fitting model was determined to be  $1.0 \pm 0.6$  nM by fluorescence titration experiments (inset of Fig. 2B). This indicates very strong binding to TAR RNA, which is comparable to even the wild Tat protein ( $K_d = 2\text{--}8$  nM).<sup>22</sup> Significantly, the affinity of FiLuP is found to be two orders of magnitude higher than that of the FRET probe examined under identical conditions ( $K_d = 360 \pm 78$  nM, Fig. S2B†). Hence, the forced intercalation of the TO unit confers advantage with regard to the binding affinity toward TAR RNA. The examination of various RNAs reveals that FiLuP is highly selective toward TAR RNA (Fig. 2C). The response for TAR RNA was more than 5-fold greater than that for non-cognate RNAs (the bacterial ribosomal RNA A-site and the influenza A virus RNA promoter region) (Fig. S3†).<sup>19e,f</sup> On the other hand, the FRET probe only exhibits moderate selectivity for TAR RNA (Fig. 2C and S3†), as reported previously.<sup>6,11</sup> We reason that the observed difference in selectivity between the two probes stems from their working principles. In the case of the FRET



probe, even non-specific binding would induce changes in FRET efficiency. In contrast, the FiLuP probe relies on the peptide's binding and the intercalation of the TO unit for the fluorescence response to occur. Non-specific binding events would not elicit a response unless the TO unit efficiently intercalates into the base pairs of target RNAs. This feature of the FIT system significantly improves the response selectivity for TAR RNA. It should be noted here that, prior to this work, our group reported that TO itself functioned as a light-up probe for TAR RNA and proposed its use for the FID assay.<sup>7d</sup> We believe TO is a useful indicator for the FID assay, but its binding affinity and signaling ability were only moderate ( $K_d = 60$  nM,  $\Phi_{\text{free}} < 0.01$ , and  $\Phi_{\text{bound}} = 0.198$ ) compared to those of the FiLuP probe ( $K_d = 1.0$  nM,  $\Phi_{\text{free}} = 0.0057$ , and  $\Phi_{\text{bound}} = 0.61$ ). Our group also reported that TO worked as a fluorogenic dye for nucleolar RNA imaging in living cells ( $\Phi_{\text{bound}} = 0.16$ ).<sup>23</sup> The examination with synthetic RNA and DNA revealed that TO prefers RNA over DNA, with a significant response to double-stranded RNA (rG/rC and rA/rU) and single-stranded rG.<sup>23</sup> In addition, TO and its derivative (TO-PRO-1) were reported as indicators in the FID assay for targeting various RNA structures including TAR RNA and the bacterial ribosomal RNA A-site,<sup>6,7a</sup> being apparently characterized as non-selective for TAR RNA. Apparently, our FiLuP probe does function distinctly from the previous Tat peptide-based probes<sup>8,11,12</sup> as well as TO itself, having prominent binding and fluorescence properties toward TAR RNA.

Related to this work, DNA-binding peptides conjugated with TO were developed for DNA analysis.<sup>24</sup> In these works, the TO unit was appended to the terminal of the peptide through a flexible spacer that enabled the TO unit to fold back and to intercalate into the DNA duplex. We thus synthesized a Tat<sub>47–57</sub> peptide probe appended with the TO unit at the N-terminal *via* a lysine linkage (named a conventional probe: TO-R<sub>49</sub>KKRRQRRR<sub>57</sub>). In comparison with FiLuP, the conventional probe exhibited a modest light-up response (35-fold) upon binding to TAR RNA (Fig. 2C). This mainly results from inefficient intercalation of the TO unit. In addition, we noticed that the background emission of the conventional probe is more than 2-fold higher than that of FiLuP, leading to a lower light-up response. This would be because of the emission originating from the back-folding of the TO unit into the peptide itself, as reported in other TO-appended PNA probes.<sup>25</sup> We also found that the selectivity of the conventional probe for TAR RNA was inferior (Fig. 2C and S3†), presumably due to the non-selective intercalation of the TO unit.<sup>26</sup> Hence, the connection of the TO unit with a short spacer at the middle of the Tat<sub>47–57</sub> peptide as if it were a substitute for the amino acids that make up the Tat peptide, a key design characteristic of FiLuP, is crucial for significant light-up response and selectivity for TAR RNA.

Furthermore, two other variant probes were examined to validate the FiLuP design (Fig. 3). The first variant had TO attached to a longer lysine residue instead of Dap (R<sub>49</sub>KKRR-(Lys-TO)-RRR<sub>57</sub>). This resulted in a significant decrease in fluorescence response, although selectivity towards TAR RNA



**Fig. 3** Fluorescence spectra of variant probes (50 nM) in the (a) absence and presence of 50 nM target RNA; (b) TAR RNA, (c) Bac rRNA and (d) influenza vRNA. Chemical structures of the variant probes are also shown: (A) incorporation of the TO unit with a lysine linkage (R<sub>49</sub>KKRR-(Lys-TO)-RRR<sub>57</sub>) and (B) R<sub>52</sub> substitution for the incorporation of the TO unit (R<sub>49</sub>KK-TO-RQRRR<sub>57</sub>). Excitation: (A) 521 nm and (B) 524 nm.

remained intact. We reason that the longer linker length results in higher flexibility that impedes the intercalation of TO into the RNA. The second variant altered the position of TO in the probe, substituting it with R<sub>52</sub> (arginine) instead (R<sub>49</sub>KK-TO-RQRRR<sub>57</sub>). This variant lacked selectivity for TAR RNA, matching previous literature that reported how R<sub>52</sub> is crucial for TAR RNA recognition.<sup>4a–c</sup> These experiments verified the significance of the TO unit's environment within the RNA-binding peptide on the probe's functions.

We then examined the thermodynamics of the binding of FiLuP to TAR RNA according to the polyelectrolyte theory proposed by Record *et al.* (ESI†).<sup>27</sup> We here determined the binding constants ( $K_a = 1/K_d$ ) from the fluorescence titration experiments in phosphate buffer (pH 7.4) containing NaCl concentrations (100–700 mM) (Fig. S4†). From the examination of the salt dependence of the binding affinity (Fig. 4), the



**Fig. 4** Salt dependence of the binding constants ( $K_a = 1/K_d$ ) of FiLuP for TAR RNA.





observed binding free energy ( $\Delta G_{\text{obs}}$ ) was divided into polyelectrolyte ( $\Delta G_{\text{pe}}$ ) and non-polyelectrolyte ( $\Delta G_{\text{t}}$ ) contributions. The  $\Delta G_{\text{pe}}$  contribution arises from the release of counterions from RNA upon binding, while the  $\Delta G_{\text{t}}$  contribution arises from other molecular interactions such as hydrogen bonds and van der Waals interactions. Interestingly, the previous study of positively charged 15-mer Tat peptide (SYG-RKKRRQRRR-PPQ) binding to TAR RNA revealed that electrostatic interaction contributes only to a limited extent to the free energy change, with the major role being played by non-polyelectrolyte interactions ( $\Delta G_{\text{obs}} = -9.9 \text{ kcal mol}^{-1}$ ,  $\Delta G_{\text{pe}} = -1.9 \text{ kcal mol}^{-1}$  and  $\Delta G_{\text{t}} = -8.0 \text{ kcal mol}^{-1}$  at 80 mM  $\text{Na}^+$  and pH 7.5).<sup>28</sup> In their analysis, the value of the slope of the linear plot of salt dependence (*cf.* Fig. 4) was obtained as  $-1.14$ , indicating the release of one counterion upon binding. The authors suggested that out of the six arginine (R) molecules present in the peptide, only one arginine is involved in electrostatic interaction with TAR RNA. This is consistent with the previous studies showing that a single arginine residue in the peptide is responsible for specific binding to TAR RNA.<sup>4</sup> In the case of the binding of FiLuP to TAR RNA, we found a linear relationship between the double logarithmic plot of the binding affinity and the salt concentrations ranging from 100 mM NaCl to 700 mM NaCl. The slope was determined to be  $-1.65$  (Fig. 4).  $\Delta G_{\text{t}}$  was found to contribute more greatly to the binding events ( $\Delta G_{\text{obs}} = -12.0 \text{ kcal mol}^{-1}$ ,  $\Delta G_{\text{pe}} = -2.1 \text{ kcal mol}^{-1}$  and  $\Delta G_{\text{t}} = -9.9 \text{ kcal mol}^{-1}$  at 110 mM  $\text{Na}^+$  and pH 7.4). It is highly likely that FiLuP can bind to TAR RNA in a similar manner to the parent Tat peptide.

Finally, a mock FID assay revealed the potential of FiLuP as the fluorescence indicator for TAR RNA (Fig. 5A). The FID assay is based on a model in which the indicator bound to target RNA is displaced by a test compound in a competitive manner. Thus, the binding capability of the test compounds can be evaluated by monitoring the change in the indicator's fluorescence during the displacement event. Three well-known small molecules capable of binding to TAR RNA with distinct modes (mitoxanthrone,<sup>9b</sup> neomycin<sup>29</sup> and ICR 191<sup>7c</sup>) were explored as test compounds. Mitoxanthrone was first identified through a virtual screening and then experimentally validated to bind to TAR RNA ( $K_{\text{d}} = 55 \text{ nM}$ ) and inhibit its interaction with Tat.<sup>9b</sup> Neomycin is also a strong binder for TAR RNA ( $K_{\text{d}} = 160 \text{ nM}$ ),<sup>29a</sup> but it is a noncompetitive inhibitor with respect to Tat that can form a ternary complex with Tat-TAR RNA; the three-nucleotide bulge (UCU, *cf.* Fig. 2A) is not the primary contact site for neomycin.<sup>29b</sup> ICR 191 was reported as a fluorescent indicator for TAR RNA with  $K_{\text{d}} = \sim 100 \text{ nM}$ . The intercalative binding of ICR 191 at the bulge site was revealed by a docking experiment, while the multi-binding to TAR RNA (TAR/ICR, TAR/ICR<sub>2</sub>, and TAR/ICR<sub>3</sub>) was revealed by fluorescence and MS experiments.<sup>7c</sup> Chloramphenicol was also used as a negative control as it specifically binds to 50S rRNA, not TAR RNA.<sup>30</sup> We examined the fluorescence changes in the 500 nM TAR RNA/FiLuP complex upon addition of 60 equivalents of the test compounds (30  $\mu\text{M}$ ). In the absence of the test compounds, strong emission of the complex was observed due



**Fig. 5** (A) Fluorescence indicator displacement (FID) assay using FiLuP. (B) Fluorescence spectra of FiLuP/TAR RNA (500 nM) in the (a) absence and presence of test compounds (30  $\mu\text{M}$ ): (b) mitoxanthrone, (c) chloramphenicol, (d) ICR191 or (e) neomycin. Excitation: 524 nm.

to the light-up response of FiLuP upon binding to TAR RNA (Fig. 5B). The addition of chloramphenicol resulted in a negligible change in the emission of the complex. This indicates that competitive binding does not occur because of the inability of chloramphenicol to bind to TAR RNA.<sup>30</sup> In sharp contrast, the addition of mitoxanthrone led to a drastic decrease in FiLuP's emission. Given that mitoxanthrone was reported to bind to the Tat-binding site in TAR RNA,<sup>9b</sup> the observed fluorescence decrease can be explained by the displacement event with the FiLuP probe. Here, importantly, almost no response was obtained for neomycin, a noncompetitive inhibitor of the Tat-TAR RNA complex. Considering its binding affinity ( $K_{\text{d}} = 160 \text{ nM}$ ) and the current experimental conditions ( $[\text{FiLuP}] = [\text{TAR RNA}] = 500 \text{ nM}$ ,  $[\text{neomycin}] = 30 \mu\text{M}$ ), it is likely that neomycin forms a ternary complex with FiLuP-TAR RNA, similar to the binding to Tat-TAR RNA. In the case of ICR 191, only a small decrease in FiLuP's emission was observed, indicating its relatively weak competitive ability. It is likely that the majority of CR191 binds to TAR RNA in a noncompetitive manner with FiLuP, forming ternary and/or higher order complexes. These results verify the unique feature of the FID assay with the FiLuP indicator for the identification of TAR RNA bulge-binding molecules, being able to discriminate between "competitive" and "noncompetitive" inhibitors. Such discrimination ability has never been achieved for all the previous indicators for TAR RNA including Tat peptide-based probes<sup>8,11,12</sup> and small molecule-based indicators.<sup>7</sup> All the previous FID assays showed considerable responses to neomycin. For



example, in the FID assay with TO as the indicator, its fluorescence was totally quenched in the presence of 5 equiv. of neomycin ( $[TO] = [TAR\ RNA] = 500\text{ nM}$ ,  $[neomycin] = 2.5\text{ }\mu\text{M}$ ).<sup>7d</sup> In the case of the FID assay with the FRET probe ( $K_d = 23.6\text{ nM}$ ),<sup>11a</sup> over 25% displacement was obtained for neomycin, and it was almost comparable to that for mitoxanthrone ( $[probe] = 50\text{ nM}$ ,  $[TAR\ RNA] = 40\text{ nM}$ ,  $[test\ compound] = 10\text{ }\mu\text{M}$ ). While the exact reason is not clear for now, the binding of FiLuP is likely to take place almost in the same manner as the binding of the parent Tat peptide to TAR RNA, which may also be supported by its high affinity and selectivity for TAR RNA (*cf.* Fig. 2) and its binding thermodynamics (*cf.* Fig. 4).

FiLuP has another promising feature as an indicator in the FID assay. As described above, FiLuP features strong binding ( $K_d = 1.0\text{ nM}$ ) and a large light-up response (450-fold increase) for TAR RNA compared to the FRET probe ( $K_d = 360\text{ nM}$ , 1.2-fold). This facilitates the FID assay to take place under stringent screening conditions. We carried out the mock FID assay using a 2 nM TAR RNA/FiLuP complex, where the wild Tat protein (9.8 kDa) was newly examined as a test compound in addition to TAR RNA-binding small molecules examined above (Fig. 5). We observed the emission enhancement of FiLuP upon addition of TAR RNA (Fig. S5†). This shows that FiLuP binding occurs even at such a low RNA concentration, in sharp contrast to the case of the previous FRET probe (Fig. S6†). The addition of Tat protein to the FiLuP/TAR RNA complex caused a large decrease in FiLuP's emission, whereas negligible response was seen for small molecules (Fig. 6). The response to Tat protein was concentration-dependent (Fig. S7†). This shows that the binding of Tat protein with TAR RNA resulted in the dissociation of FiLuP, which is reasonable considering that the Tat protein can compete with FiLuP to bind to TAR RNA due to its comparable affinity. It should be noted that mitoxanthrone with reasonably strong affinity ( $K_d = 55\text{ nM}$ )<sup>9b</sup> was unable to displace FiLuP bound to TAR RNA under the present stringent conditions, implying that the present FID assay can sieve out the super-strong competitive inhibitor

whose binding affinity is comparable to that of the wild Tat protein ( $K_d = 2\text{--}8\text{ nM}$ ).<sup>22</sup> Given the crucial role of ultra-high affinity for TAR RNA in the development of anti-HIV drugs,<sup>31</sup> we expect FiLuP to be a useful fluorescence indicator for the exploratory studies of TAR RNA-targeting drug candidates, ultimately contributing to the development of novel anti-HIV therapies.

## Conclusions

In conclusion, FiLuP has been developed as a useful fluorogenic probe for TAR RNA by replacing one amino acid in the Tat peptide with TO as if it were an amino acid surrogate. We here designed FiLuP as an advanced version of oligonucleotide-based FIT probes with TO as a base surrogate. To the best of our knowledge, this is the first report on FIT-based fluorescence sensing on peptide scaffolds. In contrast to previous FRET peptide probes, FiLuP does exhibit a significant light-up response for TAR RNA (450-fold increase at  $\lambda_{em} = 541\text{ nm}$ ,  $\Phi_{free} = 0.0057$ , and  $\Phi_{bound} = 0.61$ ), and responses are highly selective to TAR RNA over other non-cognate RNAs. Also, FiLuP does maintain a strong binding affinity ( $K_d = 1.0 \pm 0.6$ ) and is likely to bind to TAR RNA in a similar manner to the parent Tat peptide. The unique feature of FiLuP as an indicator in the FID assay is its ability to distinguish between competitive and noncompetitive inhibitors, which has never been demonstrated with all previous indicators for TAR RNA. Furthermore, thanks to its strong binding affinity and significant light-up properties, the FID assay under stringent screening conditions is possible. These features would facilitate a rigorous screening system as well as streamlining the subsequent screening procedures.<sup>19e</sup>

It should be noted here that, as demonstrated for oligonucleotide-based FIT probes,<sup>14,16,19</sup> the TO unit would be replaced by other cyanine dyes including deep-red emissive BIQ (benzo[*c,d*]indole-quinoline cyanine)<sup>19d</sup> for an improved FID assay that does not suffer from compound optical interference.<sup>32</sup> We also envision that the present design strategy is applicable to various peptide-based fluorogenic indicators targeting other druggable RNAs. In fact, preliminary experiments have shown that another FIT peptide (FiLuP), designed based on a  $\lambda N$  protein-derived peptide,<sup>33</sup> exhibits useful binding and fluorescence properties for its target boxB RNA (data not shown). Further studies are underway in these directions.

## Author contributions

Y. S. conceived the study; E. T. T. L. and A. F. U. synthesized the probes and characterized their functions. All authors analyzed the data. E. T. T. L., Y. S. and S. N. wrote the paper.

## Conflicts of interest

There are no conflicts to declare.



**Fig. 6** FID results under stringent conditions (2 nM TAR RNA/FiLuP complex) using the test compounds (120 nM: neomycin, mitoxanthrone, ICR191 or Tat protein).  $F$  and  $F_0$  denote the fluorescence intensity at 541 nm of the FiLuP/TAR RNA complex in the presence and absence of test compounds. Excitation: 524 nm.



## Acknowledgements

This work was supported by JSPS KAKENHI Grant Number 22H02099 and 23H00297.

## References

- 1 J. R. Thomas and P. J. Hergenrother, *Chem. Rev.*, 2008, **108**, 1171–1224.
- 2 (a) B. S. Morgan, J. E. Forte and A. E. Hargrove, *Nucleic Acids Res.*, 2018, **46**, 8025–8037; (b) A. U. Juru and A. E. Hargrove, *J. Biol. Chem.*, 2021, **296**, 100191; (c) A. E. Hargrove, *Chem. Commun.*, 2020, **56**, 14744–14756; (d) J. P. Falese, A. Donlic and A. E. Hargrove, *Chem. Soc. Rev.*, 2021, **50**, 2224–2243.
- 3 (a) C. Dingwall, I. Ernberg, M. J. Gait, S. M. Green, S. Heaphy, J. Karn, A. D. Lowe, M. Singh and M. A. Skinner, *EMBO J.*, 1990, **9**, 4145–4153; (b) D. Harrich, C. Ulich, L. F. Garcia-Martinez and R. B. Gaynor, *EMBO J.*, 1997, **16**, 1224–1235.
- 4 (a) B. J. Calnan, B. Tidor, S. Biancalana, D. Hudson and A. D. Frankel, *Science*, 1991, **252**, 1167–1171; (b) J. Tao and A. D. Frankel, *Proc. Natl. Acad. Sci. U. S. A.*, 1992, **89**, 2723–2726; (c) J. Tao and A. D. Frankel, *Proc. Natl. Acad. Sci. U. S. A.*, 1993, **90**, 1571–1575; (d) J. D. Puglisi, R. Tan, B. J. Calnan, A. D. Frankel and J. R. Williamson, *Science*, 1992, **257**, 76–80.
- 5 R. Paul, D. Dutta, R. Paul and J. Dash, *Angew. Chem., Int. Ed.*, 2020, **59**, 12407–12411.
- 6 S. L. Wicks and A. E. Hargrove, *Methods*, 2019, **167**, 3–14.
- 7 (a) P. N. Asare-Okai and C. S. Chow, *Anal. Biochem.*, 2011, **408**, 269–276; (b) S. Kumar, P. Kellish, W. E. Robinson Jr., D. Wang, D. H. Appella and D. P. Arya, *Biochemistry*, 2011, **51**, 2331–2347; (c) L. Qi, J. Zhang, T. He, Y. Huo and Z.-Q. Zhang, *Spectrochim. Acta, Part A*, 2017, **173**, 93–98; (d) Y. Ito, Y. Sato, N. Teramae and S. Nishizawa, *Bunseki Kagaku*, 2021, **70**, 149–157.
- 8 C. Matsumoto, K. Hamasaki, H. Mihara and A. Ueno, *Bioorg. Med. Chem. Lett.*, 2000, **10**, 1857–1861.
- 9 (a) S. Kumar, P. Kellish, W. E. Robinson, D. Wang, D. H. Appella and D. P. Arya, *Biochemistry*, 2012, **51**, 2331–2347; (b) A. C. Stelzer, A. T. Frank, J. D. Kratz, M. D. Swanson, M. J. Gonzalez-Hernandez, J. Lee, I. Andricioaei, D. M. Markovitz and H. M. Al-Hashimi, *Nat. Chem. Biol.*, 2011, **7**, 553–559; (c) N. N. Patwardhan, L. R. Ganser, G. J. Kapral, C. S. Eubanks, J. Lee, B. Sathyamoorthy, H. M. Al-Hashimi and A. E. Hargrove, *MedChemComm*, 2017, **8**, 1022–1036.
- 10 L. R. Ganser, J. Lee, A. Rangadurai, D. K. Merriman, M. L. Kelly, A. D. Kansal, B. Sathyamoorthy and H. M. Al-Hashimi, *Nat. Struct. Mol. Biol.*, 2018, **25**, 425–434.
- 11 (a) N. N. Patwardhan, Z. Cai, C. N. Newson and A. E. Hargrove, *Org. Biomol. Chem.*, 2019, **17**, 1778–1786; (b) N. N. Patwardhan, Z. Cai, A. U. Juru and A. E. Hargrove, *Org. Biomol. Chem.*, 2019, **17**, 9313–9320.
- 12 J. Li, Y.-Y. Fan, J. Wen, J. Zhang and Z.-Q. Zhang, *Anal. Chem.*, 2022, **94**, 4695–4702.
- 13 (a) B. A. Armitage, *Top. Curr. Chem.*, 2005, **253**, 55–76; (b) B. A. Armitage, *Top. Heterocycl. Chem.*, 2008, **14**, 11–29; (c) O. Suss, L. Motiei and D. Margulies, *Molecules*, 2021, **206**, 2828.
- 14 (a) O. Köhler, D. V. Jarikote and O. Seitz, *ChemBioChem*, 2005, **6**, 69–77; (b) F. Hövelmann, I. Gaspar, A. Ephrussi and O. Seitz, *J. Am. Chem. Soc.*, 2013, **135**, 19025–19032; (c) F. Hövelmann, I. Gaspar, J. Chemiolo, M. Kasper, J. Steffen, A. Ephrussi and O. Seitz, *Chem. Sci.*, 2016, **7**, 128–135.
- 15 S. B. Ebrahimi, D. Samata, H. F. Cheng, L. I. Nathan and C. A. Mirkin, *J. Am. Chem. Soc.*, 2019, **141**, 13744–13748.
- 16 (a) N. Kolevzon, D. Hashoul, S. Naik, A. Rubinstein and E. Yavin, *Chem. Commun.*, 2016, **52**, 2405–2407; (b) I. Peled and E. Yavin, *ACS Omega*, 2018, **3**, 3813–3818; (c) D. Hashoul, R. Shapira, M. Falchenko, O. Tepper, V. Paviov, A. Nissan and E. Yavin, *Biosens. Bioelectron.*, 2019, **137**, 271–278; (d) O. Tepper, H. Zheng, D. H. Appella and E. Yavin, *Chem. Commun.*, 2021, **57**, 540–543; (e) O. Tepper, I. Peled, Y. Fastman, A. Heinberg, V. Mitesser, R. Dzikowski and E. Yavin, *ACS Sens.*, 2022, **7**, 50–59; (f) O. Tepper, D. H. Appella, H. Zheng, R. Dzikowski and E. Yavin, *ACS Sens.*, 2024, **9**, 1458–1464.
- 17 (a) M. Li, T. Zengeya and E. Rozners, *J. Am. Chem. Soc.*, 2010, **132**, 8676–8681; (b) P. Gupta, T. Zengeya and E. Rozners, *Chem. Commun.*, 2011, **47**, 11125–11127; (c) T. Zengeya, M. Li and E. Rozners, *Bioorg. Med. Chem. Lett.*, 2011, **21**, 2121–2124; (d) P. Gupta, O. Muse and E. Rozners, *Biochemistry*, 2012, **51**, 11125–11127; (e) T. Zengeya, P. Gupta and E. Rozners, *Angew. Chem., Int. Ed.*, 2012, **51**, 12593–12596; (f) O. Muse, T. Zengeya, J. Mwaura, D. Hnedzko, D. W. McGee, C. T. Grewer and E. Rozners, *ACS Chem. Biol.*, 2013, **8**, 1683–1686; (g) T. Endoh, D. Hnedzko, E. Rozners and N. Sugimoto, *Angew. Chem., Int. Ed.*, 2016, **55**, 899–903; (h) T. Endoh, C. Annoni, D. Hnedzko, E. Rozners and N. Sugimoto, *Phys. Chem. Chem. Phys.*, 2016, **18**, 32002–32006; (i) I. Kumpina, N. Brodyagin, J. A. MacKay, S. D. Kennedy, M. Katkevics and E. Rozners, *J. Org. Chem.*, 2019, **84**, 13276–13298; (j) C. A. Ryan, V. Baskevics, M. Katkevics and E. Rozners, *Chem. Commun.*, 2022, **58**, 7148–7151; (k) C. A. Ryan, M. M. Rahman, V. Kumar and E. Rozners, *J. Am. Chem. Soc.*, 2023, **145**, 10497–10504.
- 18 (a) G. Devi, Z. Yuan, Y. Lu, Y. Zhao and G. Chen, *Nucleic Acids Res.*, 2014, **42**, 4008–4018; (b) D.-F. K. Toh, G. Devi, K. M. Patil, Q. Qu, M. Maraswami, Y. Xiao, T. P. Loh, Y. Zhao and G. Chen, *Nucleic Acids Res.*, 2016, **44**, 9071–9082; (c) A. A. L. Ong, D.-F. K. Toh, K. M. Patil, Z. Meng, Z. Yuan, M. S. Krishna, G. Devi, P. Haruehanroengra, Y. Lu, K. Xia, K. Okamura, J. Sheng and G. Chen, *Biochemistry*, 2019, **58**, 1319–1331; (d) J. Keszy, K. M. Patil, S. R. Kumar, Z. Shu, H. Y. Yong, L. Zimmermann, A. A. L. Ong, D.-D. K. Toh, M. S. Krishna, L. Yang, J.-L. Decout, D. Luo, M. Prabakaran, G. Chen and E. Kierzek, *Bioconjugate*



- Chem.*, 2019, **30**, 931–943; (e) M. S. Krishna, D.-F. Toh, Z. Meng, A. A. L. Ong, Z. Wang, Y. Lu, K. Xia, M. Prabakaran and G. Chen, *Anal. Chem.*, 2019, **91**, 5331–5338.
- 19 (a) T. Sato, Y. Sato and S. Nishizawa, *J. Am. Chem. Soc.*, 2016, **138**, 9397–9400; (b) T. Sato, Y. Sato and S. Nishizawa, *Chem. – Eur. J.*, 2017, **23**, 4079–4088; (c) T. Chiba, T. Sato, Y. Sato and S. Nishizawa, *Org. Biomol. Chem.*, 2017, **15**, 7765–7769; (d) Y. Yoshino, Y. Sato and S. Nishizawa, *Anal. Chem.*, 2019, **91**, 14254–14260; (e) E. T. T. Lee, Y. Sato and S. Nishizawa, *Chem. Commun.*, 2020, **56**, 14976–14979; (f) Y. Sato, H. Miura, T. Tanabe, C. U. Okeke, A. Kikuchi and S. Nishizawa, *Anal. Chem.*, 2022, **94**, 7814–7822; (g) C. U. Okeke, H. Miura, Y. Sato and S. Nishizawa, *Org. Biomol. Chem.*, 2023, **21**, 3402–3410.
- 20 B. J. Calnan, S. Biancalan, D. Hudson and A. D. Frankel, *Genes Dev.*, 1991, **5**, 201–210.
- 21 K. Anand, A. Schulte, K. Vogel-Bachmayr, K. Scheffzek and M. Geyer, *Nat. Struct. Mol. Biol.*, 2008, **15**, 1287–1292.
- 22 O. Chaloin, J.-C. Peter, J.-P. Briand, B. Masquida, C. Desgranges, S. Muller and J. Hoebeke, *Cell. Mol. Life Sci.*, 2005, **62**, 355–361.
- 23 M. He, Y. Sato and S. Nishizawa, *Analyst*, 2023, **148**, 636–642.
- 24 (a) J. R. Carreon, K. P. Mahon and S. O. Kelley, *Org. Lett.*, 2004, **6**, 517–519; (b) M. Thompson and N. W. Woodbury, *Biochemistry*, 2000, **39**, 4327–4338; (c) M. Thompson, *Biomacromolecules*, 2007, **8**, 3628–3633.
- 25 N. Svanvik, J. Nygren, G. Westman and M. Kubista, *J. Am. Chem. Soc.*, 2001, **123**, 803–809.
- 26 T. Sato, Y. Sato, K. Iwai, S. Kuge, S. Nishizawa and N. Teramae, *Chem. Commun.*, 2015, **51**, 1421–1423.
- 27 M. T. Record Jr., C. F. Anderson and T. M. Lohman, *Q. Rev. Biophys.*, 1978, **11**, 103–178.
- 28 H. Suryawanshi, H. Sabharwal and S. Maiti, *J. Phys. Chem. B*, 2010, **114**, 11155–11163.
- 29 (a) T. D. Bradrick and J. P. Marino, *RNA*, 2004, **10**, 1459–1468; (b) S. Wang, P. W. Huber, M. Cui, A. W. Czarnik and H.-Y. Mei, *Biochemistry*, 1998, **37**, 5549–5557.
- 30 (a) K. S. Long and B. T. Porse, *Nucleic Acids Res.*, 2003, **31**, 7208–7215; (b) D. Moazed and H. F. Noller, *Biochimie*, 1987, **69**, 879–884.
- 31 M. D. Shortridge, P. T. Wille, A. N. Jones, A. Davidson, J. Bogdanovic, E. Arts, J. Karn, J. A. Robinson and G. Varani, *Nucleic Acids Res.*, 2019, **47**, 1523–1531.
- 32 (a) Y. Sato, S. Yajima, A. Taguchi, K. Baba, M. Nakagomi, Y. Aiba and S. Nishizawa, *Chem. Commun.*, 2019, **55**, 3183–3186; (b) Y. Sato, Y. Aiba, S. Yajima, T. Tanabe, K. Higuchi and S. Nishizawa, *ChemBioChem*, 2019, **20**, 2752–2756.
- 33 H. S. Jeong, S. Choi, H. Kim, J. W. Park, H. N. Park, S. M. Park, S. K. Jang, Y. M. Rhee and B. H. Kim, *Mol. Biosyst.*, 2013, **9**, 948–951.

